在患有血栓塞的孕妇患者中,在血小板数量极低和正常的血小板数量时,通过血小板显微镜测定生理凝块强度
Kumiko Chino1,2, Yue Qiu1,2, Ximiao Yu2
1Department of Anesthesiology, University of Pittsburgh Medical Center, UPMC Magee Hospital, Pittsburgh, Pennsylvania.
Research and practice in thrombosis and haemostasis
|March 2, 2026
概括
通过血小板显微镜测量的最大幅度 (MA) 与患有血小板缩的孕妇患者的血小板计数有很强的相关性. 这一发现提供了对凝块强度和出血风险的生理洞察力,有助于关于神经轴麻醉的临床决策.
科学领域:
- 产科和妇科 产科和妇科
- 麻醉学 麻醉学
- 血液学 血液学 血液学
背景情况:
- 怀孕期间的血小板缺血使神经轴麻醉的决定变得复杂,指导方针通常依赖于绝对血小板计数.
- 血栓形成显微镜 (TEG) 提供实时凝块动态,可能提供比标准实验室测试更深入的生理洞察力.
- 怀孕期间TEG最大幅度 (MA) 和血小板计数之间的关系,特别是在血小板缺血状态下,仍然不完全定义.
研究的目的:
- 调查TEG最大幅度 (MA) 与孕妇患者血小板计数之间的相关性.
- 评估来自不同TEG测定 (CK,CRT,CFF) 的MA能够识别临床显著的血小板缺血 (<70×109/L) 的能力.
主要方法:
- 一项前性观察性研究招募了患有或没有血小板缺血的孕妇.
- 使用TEG 6s平台分析了血液样本,以确定MA值.
- 使用皮尔森相关性和线性回归评估了MA和血小板计数之间的相关性;接收器运行特征曲线评估了血小板减少的诊断性能.
主要成果:
- 血小板计数显示与MA-CK (r=0.75),MA-CRT (r=0.73) 和MA-CFF (r=0.52) 有很强的相关性.
- 在区分血小板计数<70×109/L (AUC=0.855) 中,MA-CK表现出最高的准确性.
- 大多数患者报告出血症状很小,在MA和出血得分之间没有发现显著的相关性;没有发生神经轴血瘤.
结论:
- 最大幅度 (MA) 是血小板数的强烈生理相关在血小板缺血分娩患者.
- 由TEG衍生的MA提供了关于血栓强度和血栓数量低的孕妇患者潜在出血风险的宝贵见解.
- TEG发现可以补充管理这些患者的临床判断,但不应该取代它.
相关概念视频
Formation of the Platelet Plug
10.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.1K
Clot Retraction and Fibrinolysis
9.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.7K
Structure and Function of Platelets
4.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Disorders of Hemostasis
2.5K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K


